Drug · CHEMBL602
CYSTEAMINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CYSTEAMINE. Drugs and targets, record CHEMBL602. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL602
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 3 of its 16 diseases, from ATC, EMA Human Drugs and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases16
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 16Source Open Targets
See all 16 diseasesTrials16
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00001213 | Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis | Phase 2 | 328 | 2014-07-22 | cysteamine | Its name | ClinicalTrials.gov |
| NCT03000348 | A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations | Phase 2 | 91 | 2021-04-14 | cysteamine | Its name | ClinicalTrials.gov |
| NCT00799578 | A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH) | Phase 1/2 | 13 | 2014-01-31 | cysteamine | Its name | ClinicalTrials.gov |
| NCT02735707 | Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | Phase 3 | 20,000 | cysteamine | Its name | ClinicalTrials.gov | |
| NCT00002110 | A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease | Phase 2 | 300 | cysteamine | Its name | ClinicalTrials.gov | |
| NCT06278948 | Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma | 140 | cysteamine | Its name | ClinicalTrials.gov | ||
| NCT02101957 | Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103) | Phase 2/3 | 96 | cysteamine | Its name | ClinicalTrials.gov | |
| NCT03883984 | Cysteamine for Asthma | Phase 1 | 60 | cysteamine | Its name | ClinicalTrials.gov | |
| NCT00001736 | New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in Cystinosis | Phase 1 | 51 | cysteamine | Its name | ClinicalTrials.gov | |
| NCT07477288 | Effectiveness of a Bilayering Serum and Cream Containing GABA, DMAE, Cysteamine, and Bakuchiol for Skin Whitening and Anti-Aging | Phase 2 | 44 | cysteamine | Its name | ClinicalTrials.gov |
1 to 10 of 16
See all 16 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials31
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL602
GET https://conductscience.org/api/drugs/v1/CHEMBL602/papers?page=2